RECURSIVE PARTITIONING ANALYSIS OF PROGNOSTIC FACTORS IN 3 RADIATION-THERAPY ONCOLOGY GROUP MALIGNANT GLIOMA TRIALS

被引:1014
作者
CURRAN, WJ
SCOTT, CB
HORTON, J
NELSON, JS
WEINSTEIN, AS
FISCHBACH, AJ
CHANG, CH
ROTMAN, M
ASBELL, SO
KRISCH, RE
NELSON, DF
机构
[1] RADIAT THERAPY ONCOL GRP,PHILADELPHIA,PA
[2] MOFFITT CANC CTR,EASTERN COOPERAT ONCOL GRP,TAMPA,FL
[3] ARMED FORCES INST PATHOL,WASHINGTON,DC 20306
[4] LATTER DAY ST HOSP,SALT LAKE CITY,UT 84143
[5] COLUMBIA PRESBYTERIAN MED CTR,NEW YORK,NY 10032
[6] SUNY DOWNSTATE MED CTR,BROOKLYN,NY
[7] VET ADM MED CTR,PHILADELPHIA,PA 19104
[8] HIGHLAND HOSP,ROCHESTER,NY 14620
[9] ALBERT EINSTEIN COLL MED,PHILADELPHIA,PA
关键词
D O I
10.1093/jnci/85.9.704
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Despite notable technical advances in therapy for malignant gliomas during the past decade, improved patient survival has not been clearly documented, suggesting that pretreatment prognostic factors influence outcome more than minor modifications in therapy. Age, performance status, and tumor histopathology have been identified as the pretreatment variables most predictive of survival outcome. However, an analysis of the association of survival with both pretreatment characteristics and treatment-related variables is necessary to assure reliable evaluation of new approaches for treatment of malignant glioma. Purpose: This study of malignant glioma patients used a nonparametric statistical technique to examine the associations of both pretreatment patient and tumor characteristics and treatment-related variables with survival duration. This technique was used to identify subgroups with survival rates sufficiently different to create improvements in the design and stratification of clinical trials. Methods: We used a recursive partitioning technique to analyze survival in 1578 patients entered in three Radiation Therapy Oncology Group malignant glioma trials from 1974 to 1989 that used several radiation therapy (RT) regimens with and without chemotherapy or a radiation sensitizer. This approach creates a regression tree according to prognostic variables that classifies patients into homogeneous subsets by survival. Twenty-six pretreatment characteristics and six treatment-related variables were analyzed. Results: The most significant split occurred by age (<50 versus greater-than-or-equal-to 50 years). Patients younger than 50 years old were categorized by histology (astrocytomas with anaplastic or atypical foci [AAF] versus glioblastoma multiforme [GBM]) and subsequently by normal or abnormal mental status for AAF patients and by performance status for those with GBM. For patients aged 50 years or older, performance status was the most important variable, with normal or abnormal-mental status creating the only significant split in the poorer performance status group. Treatment-related variables produced a subgroup showing significant differences only for better performance status GBM patients over age 50 (by extent of surgery and RT dose). Median survival times were 4.7-58.6 months for the 12 subgroups resulting from this analysis, which ranged in size from 32 to 256 patients. Conclusions: This approach permits examination of the interaction between prognostic variables not possible with other forms of multivariate analysis. Implications: The recursive partitioning technique can be employed to refine the stratification and design of malignant glioma trials.
引用
收藏
页码:704 / 710
页数:7
相关论文
共 30 条
[1]   DETERMINANTS OF IMPROVED OUTCOME IN SMALL-CELL LUNG-CANCER - AN ANALYSIS OF THE 2,580-PATIENT SOUTHWEST ONCOLOGY GROUP DATA-BASE [J].
ALBAIN, KS ;
CROWLEY, JJ ;
LEBLANC, M ;
LIVINGSTON, RB .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (09) :1563-1574
[2]  
CHANG CH, 1983, CANCER, V52, P997, DOI 10.1002/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO
[3]  
2-2
[4]  
Ciampi A., 1988, Statistical Software Newsletter, V14, P78
[5]  
COX DR, 1972, J R STAT SOC B, V34, P187
[6]  
CURRAN WJ, 1992, CANCER, V70, P2909, DOI 10.1002/1097-0142(19921215)70:12<2909::AID-CNCR2820701230>3.0.CO
[7]  
2-6
[8]   RESULTS OF A RANDOMIZED TRIAL COMPARING BCNU PLUS RADIOTHERAPY, STREPTOZOTOCIN PLUS RADIOTHERAPY, BCNU PLUS HYPERFRACTIONATED RADIOTHERAPY, AND BCNU FOLLOWING MISONIDAZOLE PLUS RADIOTHERAPY IN THE POSTOPERATIVE TREATMENT OF MALIGNANT GLIOMA [J].
DEUTSCH, M ;
GREEN, SB ;
STRIKE, TA ;
BURGER, PC ;
ROBERTSON, JT ;
SELKER, RG ;
SHAPIRO, WR ;
MEALEY, J ;
RANSOHOFF, J ;
PAOLETTI, P ;
SMITH, KR ;
ODOM, GL ;
HUNT, WE ;
YOUNG, B ;
ALEXANDER, E ;
WALKER, MD ;
PISTENMAA, DA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1989, 16 (06) :1389-1396
[9]  
GORDON L, 1985, CANCER TREAT REP, V69, P1065
[10]   INCREASING ANNUAL INCIDENCE OF PRIMARY MALIGNANT BRAIN-TUMORS IN THE ELDERLY [J].
GREIG, NH ;
RIES, LG ;
YANCIK, R ;
RAPOPORT, SI .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (20) :1621-1624